rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2
|
pubmed:dateCreated |
2002-3-1
|
pubmed:abstractText |
To determine the expected time to serum testosterone normalization after short-course neoadjuvant androgen deprivation therapy (NAAD) and three-dimensional conformal radiotherapy for patients with localized prostate cancer and to identify pretreatment predictors that correlated with the time to testosterone normalization.
|
pubmed:commentsCorrections |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0360-3016
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
52
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
439-43
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11872290-Androgen Antagonists,
pubmed-meshheading:11872290-Anilides,
pubmed-meshheading:11872290-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11872290-Humans,
pubmed-meshheading:11872290-Leuprolide,
pubmed-meshheading:11872290-Male,
pubmed-meshheading:11872290-Multivariate Analysis,
pubmed-meshheading:11872290-Neoadjuvant Therapy,
pubmed-meshheading:11872290-Nitriles,
pubmed-meshheading:11872290-Prospective Studies,
pubmed-meshheading:11872290-Prostatic Neoplasms,
pubmed-meshheading:11872290-Radiotherapy, Conformal,
pubmed-meshheading:11872290-Reference Values,
pubmed-meshheading:11872290-Regression Analysis,
pubmed-meshheading:11872290-Testosterone,
pubmed-meshheading:11872290-Time Factors,
pubmed-meshheading:11872290-Tosyl Compounds
|
pubmed:year |
2002
|
pubmed:articleTitle |
Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer.
|
pubmed:affiliation |
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
|
pubmed:publicationType |
Journal Article
|